Who is sponsoring NCT05143073?

NCT05143073 is sponsored by Virginia Commonwealth University.

What drugs are being tested in NCT05143073?

Interventions in NCT05143073: Alcohol use disorder and strategies to reduce risk educational material, Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk educational material.

What condition does NCT05143073 study?

NCT05143073 studies Alcohol Use Disorder.

Is NCT05143073 still recruiting?

NCT05143073 is currently completed. Last updated 19 January 2022.

Last reviewed 2022-01-19 · How we verify

NCT05143073

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Understanding Genetic Risk for Alcohol Use Disorder

Completed NA Last updated 19 January 2022

What this trial tests

NA trial testing Alcohol use disorder and strategies to reduce risk educational material in Alcohol Use Disorder in 338 participants. Completed in 13 December 2021.

Timeline

15 November 2021

Primary endpoint
13 December 2021

13 December 2021

Quick facts

Lead sponsor	Virginia Commonwealth University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	338
Start date	15 November 2021
Primary completion	13 December 2021
Estimated completion	13 December 2021
Sites	1 location across United States

Drugs / interventions tested

Alcohol use disorder and strategies to reduce risk educational material
Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk educational material

Conditions studied

Alcohol Use Disorder — all drugs for Alcohol Use Disorder →

Sponsor

Virginia Commonwealth University

Who can join

18 and older, any sex, with Alcohol Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate an online educational tool that will help individuals better understand alcohol use disorder, risk factors, and genetic risk information and to better understand participant's beliefs regarding alcohol use disorder. This study does not involve genetic testing. Investigators will not be giving participants any personalized genetic feedback as part of the study; however, investigators will ask participants to imagine that they receive different hypothetical genetic risk scores and respond to survey items.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Evaluating the impact of a new educational tool on understanding of polygenic risk scores for alcohol use disorder.
Driver MN, Kuo SI, Petronio L, Brockman D, et al · · 2022 · cited 7× · PMID 36506445 · DOI 10.3389/fpsyt.2022.1025483
The impact of receiving polygenic risk scores for alcohol use disorder on psychological distress, risk perception, and intentions to reduce drinking.
Driver MN, Kuo SI, Dron JS, Austin J, et al · · 2023 · cited 6× · PMID 36856135 · DOI 10.1002/ajmg.b.32933

Verify or expand the search:

Other recruiting trials for Alcohol Use Disorder

Currently open trials in the same condition.

NCT06860607 — Environment and Alcohol: A Pilot Study · Phase 1 · recruiting
NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
NCT07046819 — Tirzepatide in MetALD · Phase 2 · recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting

Other Virginia Commonwealth University trials

Trials by the same sponsor.

NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05143073 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
Last refreshed: 19 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05143073.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing